Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Algert Global LLC

Algert Global LLC raised its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 11.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 289,713 shares of the company's stock after purchasing an additional 28,955 shares during the period. Algert Global LLC owned 0.06% of Elanco Animal Health worth $3,508,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. FMR LLC boosted its holdings in shares of Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock valued at $487,213,000 after acquiring an additional 37,022,891 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Elanco Animal Health by 6.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after acquiring an additional 1,074,274 shares during the last quarter. Magnetar Financial LLC lifted its holdings in Elanco Animal Health by 13.7% in the fourth quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock valued at $145,711,000 after acquiring an additional 1,454,082 shares during the last quarter. Geode Capital Management LLC lifted its position in Elanco Animal Health by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company's stock valued at $99,102,000 after buying an additional 312,165 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Elanco Animal Health by 8.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 6,924,098 shares of the company's stock worth $83,851,000 after purchasing an additional 538,631 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Trading Up 5.1%

ELAN stock traded up $0.61 during trading on Monday, hitting $12.57. 1,863,478 shares of the company traded hands, compared to its average volume of 5,223,783. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The firm has a market capitalization of $6.24 billion, a PE ratio of 31.41, a P/E/G ratio of 2.50 and a beta of 1.49. The company has a 50-day moving average of $9.89 and a 200-day moving average of $11.42.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company's quarterly revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.34 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Morgan Stanley lowered their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus upped their price target on shares of Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday. UBS Group cut their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Piper Sandler reduced their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Finally, Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $15.00.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were bought at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.89% of the company's stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.